{
    "clinical_study": {
        "@rank": "148129", 
        "arm_group": [
            {
                "arm_group_label": "CFZ533 in healthy volunteers", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "CFZ533 in rheumatoid arthritis patients", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics,\n      and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy\n      subjects and intravenous doses in rheumatoid arthritis patients."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "This was a Healthy Volunteer only study originally, but after an amendment to protocol,\n      rheumatoid arthritis patients will be starting 7-Mar-2014 and thus, the protocol is now\n      registered."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (for healthy volunteers):\n\n          1. Healthy male and surgically sterilized or post-menopausal female subjects 18 to 55\n             years of age\n\n          2. Vital signs (systolic and diastolic blood pressure and pulse rate) should be within\n             normal limits\n\n          3. Weight 50-150 kg and a body mass index (BMI) 18-32 kg/m2\n\n        Inclusion Criteria (for rheumatoid arthritis patients):\n\n          1. Healthy male and surgically sterilized or post-menopausal female subjects 18 to 55\n             years of age\n\n          2. Fulfilled 2010 ACR/EULAR classification criteria for RA per Investigator\n\n          3. Treatment with a stable oral RA treatment regimen for \u2265 4 weeks before randomization\n\n          4. Systemic corticosteroids allowed if on a stable dose (\u2264 10 mg/day of prednisone or\n             equivalent) \u2265 4 weeks prior to randomization\n\n          5. Subjects taking NSAIDs (COX-1 or COX-2 inhibitors) as part of their RA therapy must\n             be on a stable dose for at least 4 weeks before randomization\n\n        Exclusion Criteria (for healthy volunteers):\n\n          1. History of hypersensitivity to vaccines, the study drug, or to drugs of similar\n             chemical classes (i.e., biologic agents)\n\n          2. Abnormal hematology, coagulation or inflammatory lab results\n\n          3. History or evidence of tuberculosis.\n\n        Exclusion Criteria (for rheumatoid arthritis patients):\n\n          1. Use of anti-TNF or other biologics in previous 3 months\n\n          2. Any intra-articular injection therapy (e.g., corticosteroid, hyaluronan) required for\n             treatment of acute RA flare within 4 weeks before randomization\n\n          3. Previous treatment with a B cell-depleting biologic agent or any other\n             immunomodulatory biologic agent within 5 half-lives (experimental or approved)\n\n          4. Current treatment with cyclophosphamide\n\n          5. Autoimmune disease other than RA\n\n          6. Adult juvenile rheumatoid arthritis\n\n          7. RA functional status class IV according to the ACR 1991 revised criteria\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02089087", 
            "org_study_id": "CCFZ533X2101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CFZ533 in healthy volunteers", 
                    "CFZ533 in rheumatoid arthritis patients"
                ], 
                "description": "Single dose at varying dosage levels depending on treatment assignment", 
                "intervention_name": "CFZ533", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Rheumatoid arthritis, RA, first-in-human, single ascending dose, safety, tolerability", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Anniston", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "36207-5710"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Port Orange", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32127"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lincoln", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68502"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Duncansville", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "16635"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of patients with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "7 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02089087"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The following PK parameters were determined from the plasma concentration time profile of CFZ533 using a non-compartmental method:\nAUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval\nAUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration\nAUCinf: Area under the plasma concentration-time curve from time zero to infinity", 
                "measure": "Plasma Pharmacokinetics (PK) of CFZ533: Area Under the Plasma Concentration-time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of CFZ533: Observed Maximum Plasma Concentration Following Drug Administration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of CFZ533: Systemic Clearance from Plasma (CL)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Plasma Pharmacokinetics (PK) of CFZ533: Apparent Volume of Distribution (Vss)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Determining the presence and measuring amount of anti-CFZ533 antibodies in the blood", 
                "measure": "CFZ533 immunogenicity", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}